RyosukeTsugitomi (@Rtsugitom) profile picture

RyosukeTsugitomi

@Rtsugitom

Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research

Joined September 2026
  • Tweets30
  • Following82
  • Followers33
18Media
Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)Photo by RyosukeTsugitomi (@Rtsugitom)
Transiting through Istanbul Airport! ✈️ What a HUGE airport!! 😲
Image from RyosukeTsugitomi (@Rtsugitom)
RyosukeTsugitomi (@Rtsugitom) profile pictureRyosukeTsugitomi@RtsugitomOct 27
Heading back to Japan! ✈️ Hope to be back at ESMO next year! ¡Gracias, Madrid! 🇪🇸❤️ #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
4
131
Heading back to Japan! ✈️ Hope to be back at ESMO next year! ¡Gracias, Madrid! 🇪🇸❤️ #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
1
1
3
210
The energy here is amazing! What a huge turnout! #ESMO26
1
6
347
Day 4 of #ESMO26! I’ll be presenting my poster today! If you’re attending, please check it out! Looking forward to seeing you there!
Image from RyosukeTsugitomi (@Rtsugitom)
1
3
395
Breakfast at my hotel 🍽️😋 Love the buffet-style breakfast with lots of fresh fruit🍌🍇 And amazingly, it starts as early as 4 AM! 😲
Image from RyosukeTsugitomi (@Rtsugitom)
2
87
This is so true. Totally agree! Additionally, the absence of crossover raises the bar for obtaining informed consent, both for patients and investigators.
Yakup Ergün (@dr_yakupergun) profile pictureYakup Ergün
@dr_yakupergunOct 25
“If PFS is the primary endpoint, why isn't crossover allowed?” I haven't heard a more justified complaint from an oncologist in a long time. Dr. Benjamin Besse💯👏👏 #ESMO26
95
A much larger difference than anticipated! #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
RyosukeTsugitomi (@Rtsugitom) profile pictureRyosukeTsugitomi@RtsugitomOct 25
Two highly anticipated studies will be presented at today's Presidential Symposium #ESMO26 ① KRASCENDO-1: Results from a head-to-head trial comparing two KRAS inhibitors in patients with KRAS G12C-mutated NSCLC
1
123
Is sotorasib becoming the crizotinib eventually superseded by a newer inhibitor, just as alectinib replaced crizotinib in ALK-positive NSCLC..? Thank you sotorasib, for the past. All glory to divarasib, the future!
1
1
84
teapawt.net/NEJM/status/2114380217…
NEJM (@NEJM) profile pictureNEJM
@NEJMOct 25
Presented at #ESMO26: In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: nej.md/4BiCvbk @myESMO
A graph from the Original Article "Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC.” The trial name, Krascendo 1, is in parentheses after the title. The graph shows progression-free survival in the full analysis population. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article "Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC.” The trial name, Krascendo 1, is in parentheses after the title. The graph shows progression-free survival in the full analysis population. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.

23
Although challenges remain in how best to identify MET alterations, this looks like a highly promising treatment option following progression on osimertinib! #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
RyosukeTsugitomi (@Rtsugitom) profile pictureRyosukeTsugitomi@RtsugitomOct 25
Replying to @Rtsugitom
②SAFFRON: Osimertinib + savolitinib vs. platinum-based chemotherapy in patients with EGFR-mutated, MET-overexpressed or MET-amplified NSCLC following progression on osimertinib
1
119
Are we heading back to the days when we were desperately chasing T790M through repeat biopsies..? But perhaps that's how it should be.
1
1
53
teapawt.net/NEJM/status/2114380721…
NEJM (@NEJM) profile pictureNEJM
@NEJMOct 25
Presented at #ESMO26: In patients with 𝘌𝘎𝘍𝘙-mutated and MET-altered non–small-cell lung cancer that had progressed during osimertinib therapy, osimertinib plus savolitinib (a MET tyrosine kinase inhibitor) led to longer survival than platinum–pemetrexed. Full phase 3 SAFFRON trial results: nej.md/4hXdueb @myESMO
A graph showing progression-free survival in the full analysis population.

ALT A graph showing progression-free survival in the full analysis population.

23
Two highly anticipated studies will be presented at today's Presidential Symposium #ESMO26 ① KRASCENDO-1: Results from a head-to-head trial comparing two KRAS inhibitors in patients with KRAS G12C-mutated NSCLC
1
1
193
②SAFFRON: Osimertinib + savolitinib vs. platinum-based chemotherapy in patients with EGFR-mutated, MET-overexpressed or MET-amplified NSCLC following progression on osimertinib
1
155
Another impressive set of results with sac-TMT! #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
1
125
teapawt.net/NEJM/status/2114285845…
NEJM (@NEJM) profile pictureNEJM
@NEJMOct 25
Presented at #ESMO26: Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: nej.md/4Bo3liu @myESMO
A graph from the Original Article " Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” The trial name, OptiTROP-Lung06, is in parentheses after the title. The graph shows progression-free survival as assessed by blinded independent central review. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.

ALT A graph from the Original Article " Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1–Negative Advanced NSCLC.” The trial name, OptiTROP-Lung06, is in parentheses after the title. The graph shows progression-free survival as assessed by blinded independent central review. The trial results are being presented at the European Society for Medical Oncology 2026 Congress. The logo of the New England Journal of Medicine is at the bottom.

1
1
69
The subgroup analyses by PD-L1 TPS category also provide valuable insights! #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
RyosukeTsugitomi (@Rtsugitom) profile pictureRyosukeTsugitomi@RtsugitomOct 25
Impressive results! Even in patients with high PD-L1 expression (TPS ≥50%), the addition of chemotherapy prolonged PFS! Congratulations on the publication as well! annalsofoncology.org/article… #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
1
7
3,937
Impressive results! Even in patients with high PD-L1 expression (TPS ≥50%), the addition of chemotherapy prolonged PFS! Congratulations on the publication as well! annalsofoncology.org/article… #ESMO26
Image from RyosukeTsugitomi (@Rtsugitom)
1
1
1
6
667
Image from RyosukeTsugitomi (@Rtsugitom)
1
104
Day 3 of #ESMO26 is about to begin! Another exciting day ahead, packed with highly anticipated presentations, including KRASCENDO and SAFFRON!
Image from RyosukeTsugitomi (@Rtsugitom)
1
1
125
Load more